(6R,12aR)-6-Benzo[1,3]dioxol-5-yl-2-pyridin-2-ylmethyl-2,3,6,7,12,12a-hexahydro-pyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione | 691871-72-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: (6R,12aR)-6-Benzo[1,3]dioxol-5-yl-2-pyridin-2-ylmethyl-2,3,6,7,12,12a-hexahydro-pyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione
• CAS: 691871-72-4
• 化学式: C₂₇H₂₂N₄O₄
• 分子量: 466.496
• InChiKey: DVEHXSCLDVAPRS-QFQXNSOFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.18
• 重原子数：
  35.0
• 可旋转键数：
  3.0
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  87.76
• 氢给体数：
  1.0
• 氢受体数：
  5.0

反应信息

• 作为反应物：
  描述：

  (6R,12aR)-6-Benzo[1,3]dioxol-5-yl-2-pyridin-2-ylmethyl-2,3,6,7,12,12a-hexahydro-pyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione 在 potassium tert-butylate 、 氧气 、 N,N-二异丙基乙胺 、 bromo-tris(1-pyrrolidinyl)phosphonium hexafluorophosphate 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 23.0h， 生成 (4aR,11R)-11-Benzo[1,3]dioxol-5-yl-3-pyridin-2-ylmethyl-2,3,4a,11-tetrahydro-10H-3,10,11a-triaza-benzo[b]fluorene-1,4,5-trione
  参考文献：
  名称：

  Synthesis and SAR of tetracyclic pyrroloquinolones as phosphodiesterase 5 inhibitors

  摘要：

  The synthesis of the fused tetracyclic pyrroloquinolones 9a-i in four steps is described. The PDE5 inhibitory activities of these compounds, their selectivities against PDE1, PDE2, PDE3, PDE4 and PDE6, the preclinical pharmacokinetic assessments and the in vivo efficacy in increasing intracavernosal pressure are presented and discussed. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2003.12.044
• 作为产物：
  描述：

  (1R,3r)-1,2,3,4-四氢-1-(3,4-亚甲基二氧基苯基)-9h-吡啶并[3,4-b]吲哚-3-羧酸甲酯 在 碳酸氢钠 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 25.0h， 生成 (6R,12aR)-6-Benzo[1,3]dioxol-5-yl-2-pyridin-2-ylmethyl-2,3,6,7,12,12a-hexahydro-pyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione
  参考文献：
  名称：

  Synthesis and SAR of tetracyclic pyrroloquinolones as phosphodiesterase 5 inhibitors

  摘要：

  The synthesis of the fused tetracyclic pyrroloquinolones 9a-i in four steps is described. The PDE5 inhibitory activities of these compounds, their selectivities against PDE1, PDE2, PDE3, PDE4 and PDE6, the preclinical pharmacokinetic assessments and the in vivo efficacy in increasing intracavernosal pressure are presented and discussed. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2003.12.044